No abstract

No abstract

Ameloblastoma is a benign but locally aggressive neoplasm of the odontogenic epithelium, the treatment of which is controversial. A review was made of 22 patients treated for histologically diagnosed ameloblastoma between January 1975 and January 2000. We recorded data relating to patient sex, age, site of involvement, histologic type, surgical treatment, and number of recurrences. All ameloblastomas were located in the mandible. The most common histologic patterns were follicular and plexiform lesions. A total of 22.7% of the tumors were unicystic ameloblastomas. Unicystic lesions were seen to affect younger patients than the rest of the histologic types. Eighteen patients were initially treated in our center, and 4 cases were referred to our center for secondary treatment. The number of recurrences was significantly lower in patients initially treated in our center. Primary treatment comprised enucleation and bone curettage in 10 cases and radical surgery in 7. Forty percent of the unicystic lesions and 53.3% of the non-unicystic ameloblastomas of our study presented at least 1 recurrence. Ameloblastoma is a polymorphic neoplasm for which the treatment is conditioned by a number of clinical and histologic factors. An individualized preoperative study is essential for treatment.

No abstract

Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide. Material and Methods: Two different types of treatments were applied in patients diagnosed of recurrent BRONJ in a referral hospital for 1.100.000 inhabitants. In the group A, plasma rich in growth factors was applied during the surgery. In the group B, the treatment consisted in the subcutaneous administration of teriparatide. All the cases of BRONJ should meet the following conditions: recurrent BRONJ, impossibility of surgery in stage 3 Ruggiero classification and absence of diagnosed neoplastic disease. Clinical and radiographic evolution of the patients from both groups was observed. Results: Nine patients were included, 5 in group A and 4 in group B. All the patients were women on oral bis-phosphonate therapy for primary osteoporosis (5 patients) or osteoporosis-related to the use of corticosteroids (4 patients). Alendronate was the most common oral bisphosphonate associated with BRONJ in our study (four patients in group A and two in group B). The mean age was 72,8 years in the group A and 73,5 years in the group B. All the patients from group A showed a complete resolution of their BRONJ. Only one patient in the group B showed the same evolution. Conclusions: In our series, the plasma rich in growth factors showed better results than the teriparatide in the treatment of recurrent BRONJ. Key words:Osteonecrosis, oral bisphosphonate, treatment, teriparatide, plasma rich in growth factors.